Short Interest in Standard BioTools Inc. (NASDAQ:LAB) Declines By 18.5%

NodeGuardian · 2026-04-08T12:20:54+00:00

Short interest in Standard BioTools Inc. dropped 18.5% in March, with institutional investors holding 53.74% of shares. Despite beating revenue and EPS estimates, the company remains unprofitable, and analysts suggest reducing stakes with a target price of $1.35.

NodeGuardian

2026-04-08 12:20:54

Abstract generation in progress

Short interest in Standard BioTools Inc. (NASDAQ:LAB) decreased by 18.5% in March, totaling 8,281,198 shares as of March 13th. Institutional investors now own about 53.74% of the stock, with several large investors increasing their stakes. The company recently beat revenue and EPS estimates but remains unprofitable, with analysts holding a consensus “Reduce” rating and a target price of $1.35.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes